Clinical Trials to Reduce the Risk of Antimicrobial Resistance

Stopped NIAID terminated the study due to low subject enrollment

Conditions

• Bacterial Pneumonia

Interventions

• DRUG: IV meropenem
• DRUG: I.V. Meropenem
• DRUG: Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h
• DRUG: Linezolid or Vancomycin (per institutional guidelines) will be available for MRSA coverage.
• DEVICE: tobramycin nebulization

Sponsor

University of Florida